Option Care Health Inc
$ 33.81
-6.30%
24 Feb - close price
- Market Cap 5,857,229,000 USD
- Current Price $ 33.81
- High / Low $ 35.50 / 32.08
- Stock P/E 28.64
- Book Value 8.49
- EPS 1.26
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.15 %
- 52 Week High 36.80
- 52 Week Low 24.23
About
Option Care Health, Inc. offers infusion services at home and at alternative sites in the United States. The company is headquartered in Bannockburn, Illinois.
Analyst Target Price
$39.82
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-30 | 2025-07-29 | 2025-04-21 | 2025-02-20 | 2024-10-30 | 2024-07-31 | 2024-04-23 | 2024-02-22 | 2023-10-25 | 2023-07-27 | 2023-05-03 |
| Reported EPS | 0 | 0.45 | 0.41 | 0.4 | 0.3696 | 0.31 | 0.3 | 0.26 | 0.32 | 0.31 | 0.63 | 0.21 |
| Estimated EPS | 0.4622 | 0.43 | 0.3797 | 0.3466 | 0.3623 | 0.31 | 0.27 | 0.23 | 0.29 | 0.28 | 0.22 | 0.18 |
| Surprise | -0.4622 | 0.02 | 0.0303 | 0.0534 | 0.0073 | 0 | 0.03 | 0.03 | 0.03 | 0.03 | 0.41 | 0.03 |
| Surprise Percentage | -100% | 4.6512% | 7.98% | 15.4068% | 2.0149% | 0% | 11.1111% | 13.0435% | 10.3448% | 10.7143% | 186.3636% | 16.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.41 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OPCH
2026-02-24 15:52:23
Option Care Health reported Q4 2025 financial results, with revenue of $1.47 billion and non-GAAP EPS of $0.46, both meeting analyst expectations. The company provided 2026 guidance, with adjusted EPS midpoint at $1.87 and EBITDA midpoint at $492.5 million, which aligns with market expectations. Option Care Health is recognized as the largest independent provider of home and alternate site infusion services in the U.S., demonstrating consistent revenue growth.
2026-02-24 14:52:22
Option Care Health (OPCH) reported its Q4 and full-year 2025 earnings, with revenues exceeding expectations at $1.47 billion, despite a slight miss on EPS. The company reaffirmed its 2026 guidance, expecting $5.8 billion-$6 billion in revenue and adjusted EBITDA of $480 million-$505 million, reflecting ongoing challenges from biosimilar adoption but confidence in its strategic growth initiatives and operational efficiencies. Management highlighted strong annual growth, strategic investments in clinical capabilities, and leveraging technology to enhance efficiency amidst market pressures.
2026-02-24 11:52:22
Option Care Health (NASDAQ: OPCH) reported its Q4 earnings, beating estimated EPS by 4.55% with $0.46 against an estimate of $0.44. Revenue increased by $119.00 million compared to the previous year. The company also provided guidance for FY 2026, expecting earnings between $1.82 and $1.92 per share.
2026-02-23 19:01:37
Option Care Health, Inc. (OPCH), a key player in home and alternate site infusion services, shows solid market confidence with its stock near a 52-week high. Analysts rate OPCH positively, with 11 buy ratings and an average target price suggesting an 11.57% upside given the company's strong revenue growth, profitability, and focus on reinvesting profits for expansion in the growing home healthcare market.
2026-02-23 15:09:24
Option Care Health (OPCH) is set to release its Q4 earnings, with investors focused on the company's transition away from Stelara, underlying growth momentum, and its share buyback strategy. Analysts expect EPS of 47 cents on $1.46 billion in revenue, with a consensus price target suggesting an 11.6% upside. The company has also expanded its share repurchase authorization to $1 billion.
2026-02-23 13:02:25
Tredje AP fonden has initiated a new position in Option Care Health, Inc. (NASDAQ:OPCH) by purchasing 36,683 shares valued at approximately $1.02 million in the third quarter. Other institutional investors like Swedbank AB and Boston Partners also significantly adjusted their stakes, with institutional investors now owning about 98.05% of the stock. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $37.58, following several recent upgrades and price target increases.
